Please assess the completion status of the following clinical trial:

Trial Title: GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to provide written informed consent~2. Age over 18 years~3. Relapsed/refractory lymphoma after at least 1 prior chemotherapy treatment:~   1. Hodgkin's lymphoma~  2. Aggressive non-Hodgkin's lymphoma~  3. Follicular lymphoma~4. Chemosensitive disease at time of transplantation (i.e. partial response or better to salvage chemotherapy)~5. ECOG (Eastern Cooperative Oncology Group) performance 0-2~6. Adequate organ function:~   1. Cardiac: LVEF (left ventricular ejection fraction)\>40%~  2. Pulmonary: FEV1 (forced expiratory volume at one second) and DLCO (diffusing capacity of lung for carbon monoxide)\>60% predicted~  3. Renal: creatinine \<150 µmol/L unless caused by ureteric obstruction from lymphoma~  4. Liver: No evidence of cirrhosis. ALT (Alanine Aminotransferase) and bilirubin \<2x upper limit of normal unless caused by biliary tract obstruction from lymphoma~Exclusion Criteria:~1. Clinically significant active infection~2. Active secondary central nervous system disease~3. Other serious co-morbid illness that would compromise study participation.~4. Pregnant or lactating females~5. Prior HDCT/ASCT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine/Melphalan Condition + ASCT (Type: EXPERIMENTAL): Day -1 -~* IV gemcitabine 1.5-2.5 g/m2 (depending on dose level assigned) administered as a loading bolus of 75 mg/m2, followed by a continuous infusion of 10 mg/m2/min.~* immediately following gemcitabine - IV melphalan 200 mg/m2 over 5 minutes.~Day 0~•Stem cell infusion~Patients will be assigned a dose level using the continual reassessment method based on the toxicity data available at the time of their enrollment. The dosing will start at 1.5 g/m2 and will increase by 0.5 mg/m2 at each level to a maximum of 2.5 g/m2. Dose-limiting toxicity is defined as grade 3 mucositis or skin toxicity lasting more than 3 days before downgrading, or any grade 4 non-hematological toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).